You are here: Industry Insights > ophthalmic

News List

Eluminex Biosciences, an Ophthalmology-Focused Biotechnology Company, Announces Closing of $50 Million Series A Financing prnasia
November 30, 2020
Eluminex Biosciences Limited announced the completion of a $50 million (USD) Series A Financing co-led by Lilly Asia Ventures, GL Ventures (venture capital arm of Hillhouse Capital), and Quan Capital.
Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products Sold at Wal Mart drugs
July 15, 2019
Altaire Pharmaceuticals, Inc. Issues Voluntary Recall of Multiple Ophthalmic Products Sold at Wal Mart.
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio worldpharmanews
July 02, 2019
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio.
Implandata Successfully Gains CE Mark for Next-Generation EyeMate System and Poised for European-Wide Market Launch b3cnewswire
April 17, 2019
Implandata Successfully Gains CE Mark for Next-Generation EyeMate System and Poised for European-Wide Market Launch.
FDA Approves Avaclyr for the treatment of herpetic keratitis drugs
April 17, 2019
FDA Approves Avaclyr (acyclovir ophthalmic ointment) for the Treatment of Herpetic Keratitis.
First Patient Successfully Implanted with Implandata’s Novel Eye Pressure Sensor for Continual Glaucoma Monitoring b3cnewswire
December 04, 2018
Ophthalmic medical device company Implandata Ophthalmic Products GmbH (Implandata) announced today that the first patient in its international.....
Ophthalmic Drugs Conference 2018 worldpharmanews
June 05, 2018
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs
Successful First Series C-Round Closing for Medical Device Company Implandata Ophthalmic Products GmbH b3cnewswire.
June 04, 2018
Ophthalmic medical device company Implandata Ophthalmic Products GmbH (Implandata) announced that the company accomplished a first closing of its Series C funding round. The company was able to raise a mid-single digit million
Novartis to in-licence ECF843 for ophthalmic indications globally pharmaceutical-technology
April 10, 2017
Swiss pharmaceutical company Novartis has exercised an option to in-licence ECF843 for ophthalmic indications across worldwide (outside Europe), as part of efforts to strengthen its R&D pipeline